The national negotiation policy has been implemented, with the number of negotiated drugs increasing annually and forming a normalized promotion mode. Faced with the urgent requirements of national policy promotion, hospital discipline development, and improvement of patient medical quality, the precision management of nationally negotiated drugs has become a key issue for medical institutions. Our hospital established a cost control group for nationally negotiated drugs and innovatively set up an independent "Temporary Procurement Drug Catalog for Nationally Negotiated Drugs" outside our hospital's basic drug catalog. We implemented a multidimensional precision management of nationally negotiated drugs, including drug selection, clinical application management, and monitoring and evaluation of drug usage. This study analyzes the effects of this novel pharmacy service model on the control of nationally negotiated drugs. Data on nationally negotiated drugs in a tertiary hospital from March 2021 to March 2023 were collected. The changes in relevant indicators such as hospital's nationally negotiated drug allocation and accessibility, drug utilization, and clinical usage were compared before and after the implementation of the novel pharmacy service model. The results show that after the implementation of the novel pharmacy service model, the hospital's nationally negotiated drug allocation, accessibility, procurement amount, prescription rationality rate, and clinical satisfaction rate all increased compared to before the implementation. The proportion of nationally negotiated drug expenses (total drug expenses) was <15%, controlled within a reasonable range. This novel pharmacy service model, starting from the actual clinical needs of our hospital, not only optimizes the entry and usage process of nationally negotiated drugs but also improves its supervision and evaluation system. It actively promotes the implementation of national negotiation policies while strengthening their rational use, gaining clinical recognition, and playing a positive role in the precision management of nationally negotiated drugs.

Li Li, Nan Zhou, Xianpeng Shi, Jing Li, Han Gao, Hang Feng, Peng Zhang. Effect analysis of a novel pharmacy service model on promoting precision management of nationally negotiated drug. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 10: 107-111. https://doi.org/10.25236/IJFM.2023.051017.

[1] Zhang Y., Tan Z.X., Lu Y. (2022) Implementation Status and Optimization Suggestions of the "Dual-Channel" Model for Nationally Negotiated Drugs: A Case Study of S City. Health Economics Research, 39, 15-18.

[2] Lan T., Guan L. (2022) Impact of the National Centralized Drug Procurement Policy (4+7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series. Journal of Clinical Pharmacy and Therapeutics, 47, 104– 111.

[3] Zheng D. Z., Li .S., Chen C. (2021) Research and Empirical Analysis on the Implementation of the National Negotiated Drug Policy in Fujian Province—Based on Centralized Procurement and Special Medicine Pharmacy Data. China Medical Insurance, 10, 30-35.

[4] Mao L. N., Wen X. T., Yang Y. (2021) Macro Analysis and Research on the Landing Situation of Nationally Negotiated Drugs: A Case Study of Hubei Province. China Medical Insurance, 11, 76-80.

[5] Zhang B., Ding J. X., Chen Y. (2021) Reasons and Implementation Mode of the National Medical Insurance Negotiation Drug "Dual-Channel" Policy. World Clinical Drugs, 42, 709-716.

[6] Li C., Zou J., Xu J. (2022) Analysis of the Accessibility of Nationally Negotiated Drugs in S Province under the "Dual-Channel" Model. China Medical Insurance, 11, 54-59.

[7] Chen L., Xu W., Shang B. (2020) Research on the Accessibility of Nationally Negotiated Drugs: An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou City. Health Economics Research, 37, 17-20.